佛跳墙2025 破解 蓝奏云

佛跳墙2025 破解 蓝奏云

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

佛跳墙2025 破解 蓝奏云

Learn More
Folded page of a newspaper

佛跳墙2025 破解 蓝奏云

佛跳墙2025 破解 蓝奏云

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

佛跳墙2025 破解 蓝奏云

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

佛跳墙2025 破解 蓝奏云

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

佛跳墙2025 破解 蓝奏云

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

佛跳墙2025 破解 蓝奏云

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

佛跳墙2025 破解 蓝奏云

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

p站怎么连接加速器  极光vpa  网络加速猎豹加速器  快连的服务器  surfvpn破解版  pc端vp加速器  蚂蚁加速app官网安卓  快连vpn永远能连上